Predictors of hot flushes in postmenopausal women who receive raloxifene therapy

American Journal of Obstetrics and Gynecology

Volumn 191, Issue 6, 2004, Pages 1979-1988

  Aldrighi, José M ^a   Quail, Deborah C ^b   Levy Frebault, Jacques ^c   Aguas, Fernanda ^d   Kosian, Kurt ^e   Garrido, Lurdes ^f   Goux, Brigitte Bosio Le ^b   Saráchaga, Max ^b   Graebe, Alice ^b   Niño, Antonio J ^b   Nickelsen, Thomas ^b,g  

^a Faculdade Saude Pub Da Univ S P   (Brazil)

^b ELI LILLY AND COMPANY   (United States)

^c Cabinet de Gynecologie   (France)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e Ambulatorium Menocare   (Austria)

^f Centro Hospitalar Barreiro Montijo   (Portugal)

^g LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Hot flushes; Osteoporosis; Postmenopausal women; Predictor; Raloxifene

Indexed keywords

ESTROGEN; GESTAGEN; PHYTOHORMONE; RALOXIFENE; VERALIPRIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NIGHT SWEAT; POSTMENOPAUSE OSTEOPOROSIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WAKEFULNESS;

ADMINISTRATION, ORAL; AGED; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HOT FLASHES; HUMANS; LOGISTIC MODELS; MIDDLE AGED; POSTMENOPAUSE; PROBABILITY; RALOXIFENE; RISK ASSESSMENT; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 10044273956     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2004.04.042     Document Type: Article

References (35)

1. P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, and W.J. Huster Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N Engl J Med 337 1997 1641 1647
2. B. Ettinger, D.M. Black, B.H. Mitlak, R.K. Knickerbocker, T. Nickelsen, and H.K. Genet Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial JAMA 282 1999 637 645
3. P.D. Delmas, K.E. Ensrud, J.D. Adachi, K.D. Harper, S. Sarkar, and Gennari Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial J Clin Endocrinol Metab 87 2002 3609 3617
4. E. Barrett-Connor, D. Grady, A. Sashegyi, P.W. Anderson, D.A. Cox, and K. Hoszowski Raloxifene and cardiovascular events in osteoporotic postmenopausal women JAMA 287 2002 847 857
5. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, and J.A. Cauley The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomised trial JAMA 281 1999 2189 2197
6. J.A. Cauley, L. Norton, M.E. Lippman, S. Eckert, K.A. Krueger, and D.W. Purdie Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial Breast Cancer Res Treat 65 2001 125 134
7. S.M. Boss, W.J. Huster, J. Neild, M.D. Giant, C.C. Eisenhut, and M.W. Draper Effects of raloxifene hydrochloride on the endometrium of postmenopausal women Am J Obstet Gynecol 177 1997 1458 1464
8. G.C. Davies, W.J. Huster, and W. Shen Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women Menopause 6 1999 188 195
9. P. Neven, T. Lunde, P. Benedetti-Panici, A. Tiitinen, B. Marinescu, and Devillers A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate BJOG 110 2003 157 167
10. G.C. Davies, W.J. Huster, Y. Lu, L. Plouffe, and M. Lakshmanan Adverse events reported by postmenopausal women in controlled trials with raloxifene Obstet Gynecol 93 1999 558 565
11. D. Barton, C. Loprinzi, and D. Wahner-Roedler Hot flashes: aetiology and management Drugs Ageing 18 2001 597 606
12. V. Stearns, L. Ullmer, J.F. Lopez, Y. Smith, C. Isaacs, and D.F. Hayes Hot flushes Lancet 360 2002 1851 1861
13. C.A. Staropoli, J.A. Flaws, T.L. Bush, and A.W. Moulton Predictors of menopausal hot flashes J Womens Health 7 1998 1149 1155
14. J. Wilbur, A.M. Miller, A. Montgomery, and P. Chandler Sociodemographic characteristics, biological factors, and symptoms reporting in midlife women Menopause 5 1998 43 51
15. M.S. Hunter Predictors of menopausal symptoms: psychosocial aspects Baillieres Clin Endocrinol Metab 7 1993 33 45
16. E.B. Gold, B. Sternfeld, J. Kelsey, C. Brown, C. Mouton, and D.W. Purdie Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age Am J Epidemiol 152 2000 463 473
17. E.W. Freeman, M.D. Sammel, J.A. Grisso, M. Battistini, B. Garcia-Espagna, and L. Hollander Hot flashes in the late reproductive years: risk factors for African American and Caucasian women J Womens Health 10 2001 67 76
18. P.J. Schwingl, B.S. Hulka, and S.D. Harlow Risk factors for menopausal hot flashes Obstet Gynecol 84 1994 29 34
19. J.E. Glusman, W.J. Huster, and S. Paul Raloxifene effects on vasomotor and other climacteric symptoms in postmenopausal women [abstract] Prim Care Update Obstet Gynecol 5 1998 166
20. F.J. Cohen, and Y. Lu Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials Maturitas 34 2000 65 73
21. Palacios S, Farias MLF, Luebbert H, Gomez G, Yabur JA, Quail DC, et al. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. Am J Obstet Gynecol. [In press].
22. C.L. Loprinzi, J.A. Sloan, E.A. Perez, S.K. Quella, P.J. Stella, and J.A. Mailliard Phase III evaluation of fluoxetine for treatment of hot flashes J Clin Oncol 20 2002 1578 1583
23. R. Reindollar, W. Koltun, A. Parsons, A.S. Rosen, S. Siddhanti, and L. Plouffe Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity Fertil Steril 78 2002 469 472
24. G.A. Bachmann Vasomotor symptoms in menopausal women Am J Obstet Gynecol 180 suppl 1999 S312 S316
25. G. Bachmann Physiologic aspects of natural and surgical menopause J Reprod Med 46 suppl 2001 307 315
26. C.L. Loprinzi, K.M. Zahasky, J.A. Sloan, P.J. Novotny, and S.K. Quella Tamoxifen-induced hot flashes Clin Breast Cancer 1 2000 52 56
27. E.-M. Dueker, L. Kopanski, H. Jarry, and W. Wuttke Effects of extracts from Cimicifuga racemosa on gonadotrophin release in menopausal women and ovariectomized rats Planta Med 57 1991 420 424
28. P. Amato, S. Christophe, and P.L. Mellon Estrogenic activity of herbs commonly used as remedies for menopausal symptoms Menopause 9 2002 145 150
29. D.J. McKenna, K. Jones, S. Humphrey, and K. Hughes Black cohosh: efficacy, safety and use in clinical and preclinical applications Altern Ther Health Med 7 2001 93 100
30. J.S. Jacobson, A.B. Troxel, J. Evans, L. Klaus, L. Vahdat, and D. Kinne Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer J Clin Oncol 19 2001 2739 2745
31. S. Wesel, and M. L'Hermite Clinical study of veralipride in menopausal sudden flushes Semaine Hôpitalière (Paris) 56 1980 1465 1467
32. A. David, R. Don, G. Tajchner, and L. Weissglas Veralipride: alternative anti-dopaminergic treatment for menopausal symptoms Am J Obstet Gynecol 158 1988 1107 1115
33. S. Wesel, R.P. Bourguignon, and W.B. Bosuma Veralipride versus conjugated oestrogens: a double-blind study in the management of menopausal hot flushes Curr Med Res Opin 8 1984 696 700
34. C.M. Obermeyer Menopause across cultures: a review of the evidence Menopause 7 2000 184 192
35. N.E. Avis, S.L. Crawford, and S.M. McKinlay Psychosocial, behavioral, and health factors related to menopause symptomatology Womens Health 3 1997 103 120